Scarica l'app Stockscreener
71.70
1.37%
0.97
Dopo l'orario di chiusura:
71.75
0.05
+0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$70.73
Aprire:
$71.02
Volume 24 ore:
7.44M
Relative Volume:
0.80
Capitalizzazione di mercato:
$243.07B
Reddito:
$43.59B
Utile/perdita netta:
$15.04B
Rapporto P/E:
21.23
EPS:
3.3766
Flusso di cassa netto:
$10.74B
1 W Prestazione:
+11.49%
1M Prestazione:
+6.46%
6M Prestazione:
-18.49%
1 anno Prestazione:
-43.92%
Intervallo 1D:
$70.58
$71.80
Intervallo di 1 settimana:
$64.12
$71.80
Portata 52W:
$57.00
$139.74
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
71.70 | 314.28B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
LLY
Lilly Eli Co
|
812.69 | 723.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
168.30 | 407.97B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
190.28 | 337.08B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
117.70 | 227.39B | 55.19B | 13.65B | 16.81B | 6.86 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
HIMS STOCK UPDATE: Hims & Hers Health, Inc. (NYSE:HIMS) is being Sued for Securities Fraud – Contact BFA Law by August 25 Class Action Deadline - GlobeNewswire Inc.
Hims & Hers Health, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
European ADRs Inch Higher As Drugmakers Shine - Finimize
Novo Nordisk’s GLP-1 Reign Faces New Pressures In 2025 - Finimize
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
NVO’s 2025 Market Dance: Down -51.70% – Time to Invest? - investchronicle.com
Novo Nordisk's Cardiometabolic Foundation Supports Wide Moat - Morningstar
Novo Nordisk: Navigating Challenges to Dominate Diabetes and Obesity Therapies - AInvest
The Skinny On Novo Nordisk: This Slimmed-Down Stock May Be Worth A... Shot - Finimize
NVO’s Stock Woes: Down -31.04% in 6 Months, Down -31.04% in Just 5 Days - investchronicle.com
European Stocks Shine As ADRs Climb Higher - Finimize
After ousting CEO, Novo Nordisk reclaims crown as largest European company - MSN
Why Novo Nordisk Stock Just Popped - Barchart.com
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European ADRs Show Resilience In US Market - Finimize
Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat - Morningstar
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize
What Did We Find About Insider Trading At Novo Nordisk ADR (NYSE: NVO)? - Stocksregister
European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up - MSN
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.20%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):